Special Issue

Marine Biotoxins 3.0

Message from the Guest Editor

In this new Special Issue of “Marine Biotoxins 3.0”, we welcome manuscripts dealing with microorganisms involved in the production of marine biotoxins (bacteria, cyanobacteria, dinoflagellates, diatoms, and fungi), the environmental factors favoring their proliferation, and their vectorial transfer through the marine food web. The transfer of marine biotoxins to invertebrates, fish, birds, and marine mammals constitutes a menace for wildlife. Some marine biotoxins definitely constitute a threat for human consumers of contaminated shellfish and fish, and regulatory limits need to be evaluated and discussed in order to set risk factors. Most marine biotoxins belong to different families of organic molecules, with diverse and rich chemical structures, and new biotoxins are described every year. The better we know the cellular and molecular target(s), signaling pathways and mechanism(s) used by marine biotoxins to exert their toxic activities, the more possibilities we will have to find putative antagonists or effective countermeasures.

Guest Editor

Prof. Dr. Jordi Molgó

Service d’Ingénierie Moléculaire pour la Santé (SIMoS), EMR CNRS 9004, Département Médicaments et Technologies pour la Santé (DMTS), Institut des Sciences du Vivant Frédéric Joliot, Commissariat à l’énergie Atomique et aux Énergies Alternatives (CEA), Université Paris-Saclay, Point Courrier 24, F-91191 Gif sur Yvette, France

Deadline for manuscript submissions

closed (31 May 2025)

Marine Drugs

an Open Access Journal by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed

mdpi.com/si/186428

Marine Drugs
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
marinedrugs@mdpi.com

mdpi.com/journal/marinedrugs

Marine Drugs

an Open Access Journal by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed

mdpi.com/journal/marinedrugs

About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker
Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

MDPI